LDOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Leidos Holdings Inc (LDOS) is a good buy right now for a beginner investor with a long-term focus and $50,000-$100,000 to invest. My direct view is BUY. The combination of improving defense-demand catalysts, strong hedge fund accumulation, bullish analyst coverage, and a constructive pre-market move outweighs the near-term mixed technical setup. Since the investor is impatient and does not want to wait for a perfect entry, the current pre-market price around 134.3 is acceptable for a long-term position, though not an aggressive all-in purchase.
LDOS is showing a positive short-term momentum shift: the MACD histogram is 1.402 and expanding above zero, which supports near-term upside. RSI_6 at 64.867 is neutral-to-bullish and not overextended. However, the moving averages are still bearish with SMA_200 > SMA_20 > SMA_5, meaning the longer trend has not fully reversed yet. Price is trading near resistance, with pivot 127.35, R1 132.419, and R2 135.551. The pre-market price of 134.3 is already above R1 and approaching R2, so momentum is strong, but the stock is still in a transition phase rather than a confirmed long-term breakout trend. Based on the provided similar-pattern study, LDOS has a 70% chance to rise 1.3% next day, 5.88% over the next week, and 7.06% over the next month, which supports a positive near-term setup.
["U.S. defense budget plans to rise 44% to $1.5 trillion by 2027, which is favorable for defense contractors like Leidos.", "Leidos reported a 31% revenue increase to $17 billion and secured a $2.7 billion hypersonic products contract.", "Hedge funds are buying aggressively, with buying up 348.79% over the last quarter.", "BNP Paribas initiated coverage with an Outperform rating and a $165 price target.", "Jim Cramer highlighted Leidos as worth considering during its downturn, supporting investor interest.", "Analyst commentary still broadly recognizes attractive valuation and defense priority alignment."]
["Several analysts have lowered price targets recently, signaling tempered expectations.", "Wells Fargo initiated at Equal Weight with a $165 target and flagged challenged growth and health segment drag.", "Citi, Stifel, RBC, BofA, and Jefferies all cut targets in early May, showing near-term caution.", "The stock still has bearish longer-term moving averages, so the trend is not fully repaired.", "There is no supportive insider buying trend; insiders are neutral.", "No recent congress trading data was available."]
The latest quarter information provided is the Q1 2026 season. Leidos reported a strong quarter, with revenue up 31% to $17 billion, which signals healthy top-line growth. The company also secured a $2.7 billion hypersonic products contract, reinforcing backlog and future demand visibility. Although the financial snapshot section had an error and no full earnings table was provided, the available Q1 narrative clearly points to strong growth momentum in the most recent quarter.
Analyst sentiment is mixed but still net positive. Recent coverage includes BNP Paribas initiating with Outperform and a $165 target, which is a fresh bullish signal. On the cautious side, Citi, Stifel, RBC, BofA, Jefferies, and Wells Fargo all lowered or restrained targets, reflecting concerns about near-term pricing pressure, uncertainty into 2027, and health/defense portfolio growth. The Wall Street pros view is still constructive overall because multiple firms retain Buy/Outperform ratings and acknowledge valuation appeal, but the cons view highlights slowing growth visibility and target reductions. Net-net, analysts remain positive, but with reduced upside expectations versus prior months.
